Twenty-Four Months Follow-Up of Intravitreal Bevacizumab Injection Versus Intravitreal Triamcinolone Acetonide Injection for the Management of Persistent Non-Infectious Uveitic Cystoid Macular Edema.
Adult
Aged
Angiogenesis Inhibitors
/ administration & dosage
Bevacizumab
/ administration & dosage
Female
Follow-Up Studies
Glucocorticoids
/ administration & dosage
Humans
Intravitreal Injections
Macula Lutea
/ pathology
Macular Edema
/ diagnosis
Male
Middle Aged
Retrospective Studies
Time Factors
Tomography, Optical Coherence
Treatment Outcome
Triamcinolone Acetonide
/ administration & dosage
Uveitis
/ complications
Vascular Endothelial Growth Factor A
/ antagonists & inhibitors
Visual Acuity
Young Adult
Bevacizumab
Intravitreal Injection
Triamcinolone Acetonide
Uveitic Cystoid Macular Edema
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
22
11
2017
medline:
7
1
2020
entrez:
22
11
2017
Statut:
ppublish
Résumé
To report the efficacy of intravitreal bevacizumab (IVB) injection versus intravitreal triamcinolone acetonide (IVT) for persistent non-infectious uveitic cystoid macular edema (CME). Interventional retrospective comparative case series evaluated 37 consecutive patients (44 eyes) with completely controlled uveitis and recalcitrant CME. Patients received repeated injections of 1.25 mg of IVB or 4 mg of IVT. Best-corrected visual acuity (BCVA) at baseline and 24 months was logMAR 1 and 0.8 respectively, in the IVB group (p = 0.002) and; logMAR of 1.1 and 0.6, in the IVT group (p = 0.001). Central macular thickness at baseline and 24 months was 399.2 µm and 333.7 µm (p < 0.0009), respectively, for the IVB group and; 464.4 µm and 316.5 µm in the IVT group (p = 0.044). Postoperatively, IOP increased in the IVT group. Repeated injections with IVT improve BCVA as effectively as repeated injections with IVB in the long-term management of persistent uveitic CME.
Identifiants
pubmed: 29157128
doi: 10.1080/09273948.2017.1400073
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Glucocorticoids
0
Vascular Endothelial Growth Factor A
0
Bevacizumab
2S9ZZM9Q9V
Triamcinolone Acetonide
F446C597KA
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM